Chronic kidney disease, anemia, and epoetin [1]

New England Journal of Medicine

Volumn 356, Issue 9, 2007, Pages 956-959

  Riley, David S ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; HEME; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; TISSUE INJURY; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; NOTE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; DRUG ADMINISTRATION; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; EPOETIN ALFA; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, SUBCUTANEOUS;

EID: 33847380271     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc063535     Document Type: Letter

References (2)

1. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
2. Nissenson AR, Berns JS, Sakiewicz P, et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003;42:325-30.